| P2093 | author name string | Fang Wang | |
| | Xu Zhang | |
| | Meng Xu | |
| | Jing Hu | |
| | Ke Yang | |
| | Qingshan Li | |
| | Xiaokun Wang | |
| | Kenneth K W To | |
| | Liwu Fu | |
| P2860 | cites work | Human ATP-binding cassette (ABC) transporter family | Q21245457 |
| | Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line | Q24338329 |
| | Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters | Q24617999 |
| | The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer | Q27682565 |
| | Ceritinib in ALK-rearranged non-small-cell lung cancer | Q27852989 |
| | Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function | Q28475378 |
| | Targeting multidrug resistance in cancer | Q29616803 |
| | Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes | Q31932176 |
| | The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux | Q32046906 |
| | Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. | Q33194953 |
| | Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump | Q33204719 |
| | Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway | Q33296974 |
| | Biochemical, cellular, and pharmacological aspects of the multidrug transporter | Q33636699 |
| | Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. | Q34135435 |
| | Role of ABCG2/BCRP in biology and medicine | Q34482976 |
| | Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). | Q34743441 |
| | Activation of the PI3K/Akt pathway and chemotherapeutic resistance | Q35046899 |
| | Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo | Q35067898 |
| | ABC transporter architecture and mechanism: implications from the crystal structures of BtuCD and BtuF. | Q35757366 |
| | Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein | Q36166672 |
| | Role of the breast cancer resistance protein (ABCG2) in drug transport | Q36250753 |
| | The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research | Q36365560 |
| | ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein | Q36611278 |
| | Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 | Q37119716 |
| | ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance | Q38510908 |
| | Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters | Q39854362 |
| | Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. | Q39881351 |
| | Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol | Q40036920 |
| | Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance | Q40050525 |
| | The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. | Q40254927 |
| | Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo | Q40345597 |
| | Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. | Q40410062 |
| | Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. | Q40530013 |
| | Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. | Q40904151 |
| | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2, | Q42710837 |
| | Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression | Q42815260 |
| | Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells | Q42827076 |
| | HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. | Q44450066 |
| | Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance | Q44687014 |
| | Screening novel, potent multidrug-resistant modulators from imidazole derivatives | Q45011364 |
| P433 | issue | 42 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| | ceritinib | Q21011233 |
| | overexpression | Q61643320 |
| P304 | page(s) | 44643-44659 | |
| P577 | publication date | 2015-11-09 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo | |
| P478 | volume | 6 | |